Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Atrium Therapeutics Inc (RNA)

Atrium Therapeutics Inc (RNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Mon Apr 20, 9:46PM CDT

SAN DIEGO , April 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment...

RNA : 14.30 (-0.76%)
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies PR Newswire - Fri Feb 27, 8:19AM CST

Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform

RNA : 14.30 (-0.76%)
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference PR Newswire - Thu Feb 26, 3:02PM CST

SAN DIEGO , Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 14.30 (-0.76%)
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders PR Newswire - Mon Feb 23, 7:00AM CST

SAN DIEGO , Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 14.30 (-0.76%)
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 PR Newswire - Wed Feb 18, 4:00PM CST

Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicing

RNA : 14.30 (-0.76%)
Avidity Biosciences Announces Expected Record Date for Spin-Off PR Newswire - Mon Feb 2, 8:44PM CST

SAN DIEGO , Feb. 2, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide...

RNA : 14.30 (-0.76%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBHC, RNA, NEW, and TWO PR Newswire - Fri Jan 30, 9:46PM CST

NEW YORK , Jan. 30, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

RNA : 14.30 (-0.76%)
NWE : 72.33 (-0.21%)
TWO : 11.02 (-0.90%)
TBHC : 0.9399 (+1.09%)
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights PR Newswire - Mon Dec 1, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

ATXS : 12.58 (+0.64%)
TCBX : 41.78 (-0.81%)
RNA : 14.30 (-0.76%)
FSUN : 39.45 (+0.84%)
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN PR Newswire - Mon Dec 1, 2025

NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

ATXS : 12.58 (+0.64%)
TCBX : 41.78 (-0.81%)
RNA : 14.30 (-0.76%)
FSUN : 39.45 (+0.84%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-WTRG, RNA, FIZN, and TCBX PR Newswire - Fri Nov 21, 2025

NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

TCBX : 41.78 (-0.81%)
RNA : 14.30 (-0.76%)
FIZN : 75.0100 (+5.20%)
WTRG : 39.79 (+2.03%)

Barchart Exclusives

Datadog and JFrog Are 2 Software Stocks to Buy Now According to Morgan Stanley Barchart - 1 minute ago
A Morgan Stanley analyst has picked Datadog and JFrog as top picks in its software AI list. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.